Ozan Pamir Biography and Net Worth

CFO of Niagen Bioscience

Ozan Pamir serves as Chief Financial Officer of Niagen Bioscience, where he leads the company's financial strategy, reporting, and investor relations.

Prior to joining Niagen Bioscience, Mr. Pamir served as Chief Financial Officer of 180 Life Sciences, a NASDAQ-traded biotechnology company focused on inflammatory disease treatments, where he successfully managed the company's NASDAQ listing and multiple funding rounds. His biotech experience extends to CFO and board member roles at two additional early-stage biotech companies.

Previously, Mr. Pamir was Vice President of Investment Banking at a leading independent investment bank, where he co-founded the Origination department and specialized in advising small and mid-cap life sciences companies on corporate strategy, financing, and M&A activities.

Mr. Pamir holds an Economics and Finance degree from McGill University and is a CFA Charterholder.

What is Ozan Pamir's net worth?: The estimated net worth of Ozan Pamir is at least $14.87 thousand as of November 14th, 2025. Pamir owns 2,220 shares of Niagen Bioscience stock worth more than $14,874 as of December 4th. This net worth approximation does not reflect any other investments that Pamir may own. Learn More about Ozan Pamir's net worth.
How do I contact Ozan Pamir?: The corporate mailing address for Pamir and other Niagen Bioscience executives is 10900 WILSHIRE BLVD, SUITE 600, LOS ANGELES, CA, 90024. Niagen Bioscience can also be reached via phone at (310) 388-6706 and via email at [email protected]. Learn More on Ozan Pamir's contact information.
Has Ozan Pamir been buying or selling shares of Niagen Bioscience?: During the last quarter, Ozan Pamir has bought $45,613.65 of Niagen Bioscience stock. Most recently, on Friday, November 14th, Ozan Pamir bought 4,465 shares of Niagen Bioscience stock. The stock was acquired at an average cost of $6.81 per share, with a total value of $30,406.65. Following the completion of the transaction, the chief financial officer now directly owns 7,372 shares of the company's stock, valued at $50,203.32. Learn More on Ozan Pamir's trading history.
Who are Niagen Bioscience's active insiders?: Niagen Bioscience's insider roster includes Stephen Block (Director), Robert Fried (CEO), Frank Jaksch, Jr. (Director), Ozan Pamir (CFO), and Kristin Patrick (Director). Learn More on Niagen Bioscience's active insiders.
Are insiders buying or selling shares of Niagen Bioscience?: In the last twelve months, Niagen Bioscience insiders bought shares 2 times. They purchased a total of 6,685 shares worth more than $45,613.65. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 37,161 shares worth more than $230,026.59. The most recent insider tranaction occured on November, 14th when CFO Ozan Pamir bought 4,465 shares worth more than $30,406.65. Insiders at Niagen Bioscience own 9.4% of the company. Learn More about insider trades at Niagen Bioscience.
Information on this page was last updated on 11/14/2025.

Ozan Pamir Insider Trading History at Niagen Bioscience

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/14/2025	Buy	4,465	$6.81	$30,406.65	7,372
11/14/2025	Buy	2,220	$6.85	$15,207.00	2,220
11/22/2024	Buy	2,907	$7.36	$21,395.52	2,907

Ozan Pamir Buying and Selling Activity at Niagen Bioscience

Niagen Bioscience Company Overview

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Today's Range

Now: $6.70

$6.51

$6.71

50 Day Range

MA: $7.28

$6.40

$9.90

2 Week Range

Now: $6.70

$5.16

$14.69

Volume

581,224 shs

Average Volume

833,772 shs

Market Capitalization

$534.73 million

P/E Ratio

27.92

Dividend Yield

N/A

Beta

2.31